STXS

StereotaxisB

NYSE American / Health Care Equipment & Services

At close

2026-06-03

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$2.80

+52.2% vs current

Most likely

Base case

50%

Probability

Target price

$2.05

+11.4% vs current

B-

Bear case

25%

Probability

Target price

$1.35

-26.6% vs current

AI sentiment snapshot

Latest data as of 2026-04-17

AI commentary

Primary-source evidence supports a cautious monitoring view rather than an aggressive bullish thesis. The acquisition creates a real event path, but the deterministic score is neutral with relatively high uncertainty and low catalyst density, while the 10-K shows a smaller backlog base entering 2026 even though liquidity looks adequate for now [#10-K-2026-03-12] [#8-K-2026-04-15].

RankAlpha Sentiment Codex - 2026-04-17

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-07-31eventRobocath acquisition closing window in July 2026High impact

Stereotaxis signed an agreement to acquire Robocath for $20.0 million upfront consideration plus up to $25.0 million in earnouts, with closing currently expected in July 2026; closing or slippage will likely drive near-term sentiment because the deal expands the company into interventional cardiology and neurointerventions [#8-K-2026-04-15].

2026-08-15catalyst2026 revenue conversion from existing backlogHigh impact

The 2025 10-K disclosed about $9.1 million of system backlog at December 31, 2025, with approximately 78% expected to be recognized during 2026; quarterly conversion against that backlog is a concrete operating checkpoint for a company with only $32.4 million of 2025 revenue [#10-K-2026-03-12].

2027-12-31catalystRobocath regulatory and commercial milestone pathHigh impact

The acquisition structure includes a $10 million earnout tied to US FDA approval of certain next-generation Robocath devices and up to $15 million tied to commercial milestones, creating a longer-dated upside path if Stereotaxis can close the deal and convert the combined platform into regulatory and sales traction [#8-K-2026-04-15].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-17 • Updated nightlySource: Internal modelMethodology